ARM-210 is under clinical development by ARMGO Pharma and currently in Phase II for Ventricular Tachycardia. According to GlobalData, Phase II drugs for Ventricular Tachycardia have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ARM-210’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ARM-210 overview

ARM-210 is under development for the treatment of ryanodine receptor type 1-related myopathies, catecholaminergic polymorphic ventricular tachycardia (CPVT). The drug candidate is a small molecule and is administered through oral route. It is a RyR1 calcium release channel stabilizer (a Rycal compound). It is developed based on ryanodine receptor technology.

The drug candidate was also under development for the treatment of Becker and limb-girdle muscular dystrophies, sarcopenia, Duchenne muscular dystrophy (DMD), cachexia and spinal-bulbar muscular atrophy (Kennedy’s disease).

ARMGO Pharma overview

ARMGO Pharma (ARMGO), is a pharmaceutical drug development company. The company specializes in developing small molecule drugs that repair leaky ryanodine receptor (RyR) calcium channels associated with human diseases. Its service offerings include clinical trials, drug development, drug discovery, research and development services. The company conducts clinical trials on the life-threatening cardiac disease catecholaminergic polymorphic ventricular tachycardia (CPVT), and the severe muscle disease ryanodine receptor 1-related myopathy (RYR1-RM). It operates with an additional office in Naarden, North Holland, the Netherlands. ARMGO is headquartered in New York, the US.

For a complete picture of ARM-210’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.